GlassScriptPhysician profile
Andrea R Lowden
NPI 1417181298
$25,212.66
in general payments reported to CMS, 2019-2025
15 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.31 · 2022: $109 · 2023: $118 · 2024: $6,060 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $3,424 · Food and Beverage: $3,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,364.00 |
| Travel and Lodging | $3,424.21 |
| Food and Beverage | $3,279.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $11,502.84 | 2023-2025 | Fintepla, Briviact |
| Otter Pharmaceuticals, LLC | $5,788.65 | 2024-2025 | Sympazan |
| Biocodex, INC. | $4,676.81 | 2025 | |
| Livanova USA, INC. | $2,203.75 | 2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Neuropace, INC. | $337.27 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $211.52 | 2025 | |
| Sk Life Science, INC. | $170.30 | 2025 | |
| Biomarin Pharmaceutical INC. | $108.59 | 2022 | |
| Upsher-Smith Laboratories LLC | $70.63 | 2025 | |
| Neurelis, INC. | $53.31 | 2025 | Valtoco |
| Acadia Pharmaceuticals INC | $26.76 | 2025 | Daybue |
| Nobelpharma America, LLC | $24.92 | 2025 | |
| Sumitomo Pharma America, INC. | $19.93 | 2023 | Aptiom |
| Aucta Pharmaceuticals, INC. | $17.38 | 2025 | Motpoly Xr |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Lowden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.